Nanomaterial penetration

Toxicology of the Skin

Volumn , Issue , 2010, Pages 333-346

  Monteiro Riviere, Nancy A ^a   Baroli, Biancamaria ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77958477177     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (81)

1. Woodrow Wilson Center Nanotechnology Consumer Products Inventory. Available at: http://www.nanotechproject.org. Accessed April 17, 2009.
2. Colvin V. The potential environmental impact of engineered nanomaterials. Nat Biotechnol 2003; 21:1166-1170.
3. Roco M, Bainbridge W. Societal Implications of Nanoscience and Nanotechnology. Arlington: National Science Foundation, 2001.
4. Elias PM. Stratum corneum defensive functions: an integrated view. J Invest Dermatol 2005; 125(2):183-200.
5. Barak O, Treat JR, James WD. Antimicrobial peptides: effectors of innate immunity in the skin. Adv Dermatol 2005; 21:357-374.
6. Niyonsaba F, Nagaoka I, Ogawa H. Human defensins and cathelicidins in the skin: beyond direct antimicrobial properties. Crit Rev Immunol 2006; 26:545-576.
7. Braff MH, Gallo RL. Antimicrobial peptides: an essential component of the skin defensive barrier. Curr Top Microbiol Immunol 2006; 306:91-110.
8. Lee SH, Jeong SK, Ahn SK. An update of the defensive barrier function of skin. Yonsei Med J 2006; 47(3):293-306.
9. Mathers AR, Larregina AT. Professional antigen-presenting cells of the skin. Immunol Res 2006; 36:127-136.
10. Seiffert K, Granstein RD. Neuroendocrine regulation of skin dendritic cells. Ann N Y Acad Sci 2006; 1088:195-206.
11. Berger CL, Vasquez JG, Shofner J, et al. Langerhans cells: mediators of immunity and tolerance. Int J Biochem Cell Biol 2006; 38:1632-1636.
12. Von Stebut E. Immunology of cutaneous leishmaniasis: the role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 2007; 17:115-122.
13. Bickers DR, Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 2006; 126:2565-2575.
14. Strolin Benedetti M, Whomsley R, Baltes EL. Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult population. Expert Opin Drug Metab Toxicol 2005; 1(3):447-471.
15. Baron JM, Holler D, Schiffer R, et al. Expression of multiple cytochrome P450 enzymes and multidrug resistance-associated transport proteins in human skin keratinocytes. J Invest Dermatol 2001; 116:541-548.
16. Ahmad N, Mukhtar H. Cytochrome P450: a target for drug development for skin diseases. J Invest Dermatol 2004; 123:417-425.
17. Oesch F, Fabian E, Oesch-Bartlomowicz B, et al. Drug-metabolizing enzymes in the skin of man, rat, and pig. Drug Metab Rev 2007; 39:659-698.
18. Merk HF, Baron JM, Neis MM, et al. Skin: major target organ of allergic reactions to small molecular weight compounds. Toxicol Appl Pharmacol 2007; 224:313-317.
19. Swarbrick J, Lee G, Brom J, et al. Drug permeation through human skin II: permeability of ionizable compounds. J Pharm Sci 1984; 73(10):1352-1355.
20. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci 2001; 14(2):101-114.
21. Wagner H, Kostka KH, Lehr CM, et al. pH profiles in human skin: influence of two in vitro test systems for drug delivery testing. Eur J Pharm Biopharm 2003; 55(1):57-65.
22. Elias PM. Epidermal lipids, barrier function, and desquamation. J Invest Dermatol 1983; 80(suppl):44s-49s.
23. Al-Amoudi A, Dubochet J, Norlén L. Nanostructure of the epidermal extracellular space as observed by cryo-electron microscopy of vitreous sections of human skin. J Invest Dermatol 2005; 124(4):764-777.
24. Bouwstra JA, Ponec M. The skin barrier in healthy and diseased state. Biochim Biophys Acta 2006; 1758(12):2080-2095.
25. Tang H, Mitragotri S, Blankschtein D, et al. Theoretical description of transdermal transport of hydrophilic permeants: application to low frequency sonophoresis. J Pharm Sci 2001; 90(5):545-568.
26. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 2004; 56(5):657-711.
27. Kierszenbaum AL. Integumentary system. In: Kierszenbaum AL, ed. Histology and Cell Biology. An Introduction to Pathology. St Louis: Mosby, Inc., 2002:299-318.
28. Hirokawa T, Okamoto H, Gosyo Y, et al. Simultaneous monitoring of inorganic cations, amines and amino acids in human sweat by capillary electrophoresis. Anal Chim Acta 2007; 581(1):83-88.
29. Meyer F, Laitano O, Bar-Or O, et al. Effect of age and gender on sweat lactate and ammonia concentrations during exercise in the heat. Braz J Med Biol Res 2007; 40(1): 135-143.
30. Stefaniak AB, Harvey CJ. Dissolution of materials in artificial skin surface film liquids. Toxicol In Vitro 2006; 20(8):1265-1283.
31. Patterson MJ, Galloway SD, Nimmo MA. Variations in regional sweat composition in normal human males. Exp Physiol 2000; 85(6):869-875.
32. Roberts MS. Skin structure and function. Proceedings of the Preconference Course Fundamentals of Percutaneous Penetration. Perspective in percutaneous penetration, La Grande Motte, France, Apr 13, 2004.
33. Magnusson BM, Walters KA, Roberts MS. Veterinary drug delivery: potential for skin penetration enhancement. Adv Drug Deliv Rev 2001; 50(3):205-227.
34. Otberg N, Richter H, Schaefer H, et al. Variations of hair follicle size and distribution in different body sites. J Invest Dermatol 2004; 122(1):14-19.
35. Toll R, Jacobi U, Richter H, et al. Penetration profile of microspheres in follicular targeting of terminal hair follicles. J Invest Dermatol 2004; 123(1):168-176.
36. Scheuplein RJ. Mechanism of percutaneous absorption (II): transient diffusion and the relative importance of various routes of skin penetration. J Invest Dermatol 1967; 48(1):79-88.
37. Szabo G. The number of eccrine sweat glands in human skin. Adv Biol Skin 1962; 3:1-5.
38. Lademann J, Weigmann H-J, Rickmeyer C, et al. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol 1999; 12(5):247-256.
39. Dokka S, Cooper SR, Kelly S, et al. Dermal delivery of topically applied oligonucleotides via follicular transport in mouse skin. J Invest Dermatol 2005; 124(5):971-975.
40. Carrer DC, Vermehren C, Bagatolli LA. Pig skin structure and transdermal delivery of liposomes: a two photon microscopy study. J Control Release 2008; 132:12-20.
41. Baroli B, Ennas MG, Loffredo F, et al. Penetration of metallic nanoparticles in human full-thickness skin. J Invest Dermatol 2007; 127:1701-1712.
42. Monteiro-Riviere NA, Inman AO, Ryman-Rasmussen JP. Dermal effects of nanomaterials. In: Monteiro-Riviere NA, Tran CL, eds. Nanotoxicology: Characterization, Dosing, and Health Effects. New York: Informa Healthcare, 2007:317-337.
43. Baroli B. Nanoparticles and skin penetration. are there any potential toxicological risks? J Consum Prot Food Saf 2008; 3(3):1-2.
44. Baroli B. Penetration of nanoparticles and nanomaterials in the skin: fiction or reality? J Pharm Sci 2009; [Epub ahead of print].
45. Monteiro-Riviere NA. Comparative anatomy, physiology, and biochemistry of mammalian skin. In: Hobson DW, ed. Dermal and Ocular Toxicology: Fundamentals and Methods. New York: CRC Press, 1991:3-71.
46. Barry BW. Breaching the skin’s barrier to drugs. Nat Biotechnol 2004; 22(2):165-167.
47. Zhang LW, Monteiro-Riviere NA. Assessment of quantum dot penetration into intact, tape stripped, abraded, and flexed rat skin. Skin Pharmacol Physiol 2008; 21:166-180.
48. Zhang LW, Yu WW, Colvin VL, et al. Biological interactions of quantum dot nanoparticles in skin and in human epidermal keratinocytes. Toxicol Appl Pharmacol 2008; 228:200-211.
49. Michalet X, Pinaud FF, Bentolila LA, et al. Quantum dots for live cells, in vivo imaging, and diagnostics. Science 2005; 307:538-544.
50. Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA. Penetration of intact skin by quantum dots with diverse physicochemical properties. Toxicol Sci 2006; 91:159-165.
51. Ryman-Rasmussen JP, Riviere JE, Monteiro-Riviere NA. Surface coatings determine cytotoxicity and irritation potential of quantum dot nanoparticles in epidermal keratinocytes. J Invest Dermatol 2007; 127:143-153.
52. Schmid-Wendtner MH, Korting HC. The pH of the skin surface and its impact on the barrier function. Skin Pharmacol Physiol 2006; 19:296-302.
53. Van der Merwe D, Brooks JD, Gehring R, et al. A physiologically based pharmacokinetic model of organophosphate dermal absorption. Toxicol Sci 2006; 89:188-204.
54. Monteiro-Riviere NA, Zhang LW. Assessment of quantum dot penetration into skin in different species under different mechanical actions. In: Linkov I, Steevens J, eds. Nanomaterials: Risks and Benefits. Dordrecht, Netherlands: Springer, 2008:41-52.
55. Monteiro-Riviere NA, Inman AO. Evaluation of quantum dot nanoparticle penetration in human skin. Toxicol CD Off J Soc Toxicol 2008; 102(suppl 1):21135.
56. Sapra B, Jain S, Tiwary AK. Percutaneous permeation enhancement by terpenes: mechanistic view. AAPS J. 2008; 10(1):120-132.
57. Dos Anjos JLV, Alonso A. Terpenes increase the partitioning and molecular dynamics of an amphipathic spin label in stratum corneum membranes. Int J Pharm 2008; 350(1-2):103-112.
58. Cross SE, Innes B, Roberts MS, et al. Human skin penetration of sunscreen nanoparticles: in-vitro assessment of a novel micronized zinc oxide formulation. Skin Pharmacol Physiol 2007; 20:148-154.
59. Gamer AO, Leibold E, van Ravenzwaay B. The in vitro absorption of microfine zinc oxide and titanium dioxide through porcine skin. Toxicol In Vitro 2006; 20(3):301-307.
60. Lansdown AB, Taylor A. Zinc and titanium oxides: promising UV-absorbers but what influence do they have on the intact skin? Int J Cosmet Sci 1997; 19(4):167-172.
61. Nohynek GJ, Lademann J, Ribaud C, et al. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit Rev Toxicol 2007; 37:251-277.
62. Lavrijsen APM, Bouwstra JA, Gooris GS, et al. Reduced skin barrier function parallels abnormal stratum corneum lipid organization in patients with lamellar ichthyosis. J Invest Dermatol 1995; 105:619-624.
63. Weerheim A, Ponec M. Determination of stratum corneum lipid profile by tape stripping in combination with high performance thin-layer chromatography. Arch Dermatol Res 2001; 293:191-199.
64. Monteiro-Riviere NA. Integument. In: Dellmann HD, Eurell J, eds. Textbook of Veterinary Histology. Baltimore: Williams and Wilkins, 1998:303-332.
65. Monteiro-Riviere NA. Anatomical factors affecting barrier function. In: Zhai H, Maibach HI, eds. Dermatotoxicology. 6th ed. Washington, D.C.: CRC Press, 2004: 42-70.
66. Schaefer H, Watts F, Brod J, et al. Follicular penetration. In: Scott RC, Guy RH, Hadgraft J, eds. Prediction of Percutaneous Penetration. Methods, Measurements, Modeling. London: IBC Technical Service, 1990:163-732.
67. Lauer AC, Ramachandran C, Lieb LM, et al. Targeted delivery to the pilosebaceous unit via liposomes. Adv Drug Deliv Rev 1996; 18:311-324.
68. Alvarez-Roman R, Naik A, Kalia YN, et al. Skin penetration and distribution of polymeric nanoparticles. J Control Release 2004; 99:53-62.
69. Shim J, Seok KH, Park WS, et al. Transdermal delivery of minoxidil with block copolymer nanoparticles. J Control Release 2004; 97:477-484.
70. Meidan VM, Bonner MC, Michniak BB. Transfollicular drug delivery—is it a reality? Int J Pharm 2005; 306:1-14.
71. Vogt A, Combadiere B, Hadam S, et al. 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin. J Invest Dermatol 2006; 126:1316-1322.
72. Monteiro-Riviere NA. Anatomical factors that affect barrier function. In: Zhai H, Wilhelm KP, Maibach HI, eds. Dermatotoxicology. New York: CRC Press, 2008:39-50.
73. Tinkle SS, Antonini JM, Rich BA, et al. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ Health Perspect 2003; 111:1202-1208.
74. Rouse JG, Yang J, Ryman-Rasmussen JP, et al. Effects of mechanical flexion on the penetration of fullerene amino acid-derivatized peptide nanoparticles through skin. Nano Lett 2007; 7:155-160.
75. Schaefer H, Redelmeier TE. Skin barrier. In: Schaefer H, Redelmeier TE, eds. Skin Barrier: Principles of Percutaneous Absorption. Basel, Switzerland: Karger, 1996:146-148.
76. Treffel P, Gabrad B. Skin penetration and sun protection factor of ultra-violet filters from two vehicles. Pharm Res 1996; 13:770-774.
77. Hostýnek JJ, Dreher F, Pelosi A, et al. Human stratum corneum penetration by nickel: in vivo study of depth distribution after occlusive application of the metal as powder. Acta Derm Venereol Suppl (Stockh) 2001; 212:5-10.
78. Fent KW, Jayaraj K, Gold A, et al. Tape-strip sampling for measuring dermal exposure to 1,6-hexamethylene diisocyanate. Scand J Work Environ Health 2006; 32:225-240.
79. Orentreich N, Orentreich DS. Dermabrasion. Dermatol Clin 1995; 15:313-327.
80. Grimes PE. Microdermabrasion. Dermatol Surg 2005; 31:1160-1165.
81. Lee WR, Shen SC, Wang KS, et al. Lasers and microdermabrasion enhance and control topical delivery of vitamin C. J Invest Dermatol 2003; 121:1118-1125.